BIOGRAPHICAL SKETCH
Peggy C.R. Marconi, Ph.D.
Place of Birth : Caracas, Venezuela
Date of Birth : November 04,1966
Citizenship: Italian
Present position and title: Full Professor, Ph.D.
Full Professor in Microbiology
Department of Chemical and Pharmaceutical Sciences (DipSCF)
University of Ferrara
Via Fossato di Mortara 64/A, 44121 Ferrara, Italy
Phone number: +39-0532-455381
e-mail: mcy@unife.it
ORCID link http://orcid.org/0000-0003-3488-0491
Scopus Author ID: 7004929498
Language skills: Spanish, Italian, English, French.
EDUCATION
1985/1990 University of Bologna, Italy; BS, , Biological Sciences 110/110 full marks cum laude
1990/1994 University of Ferrara, Italy; Ph.D student, Biothecnologies
1993/1994 University of Pittsburgh, Ph.D fellow, Virology and Molecular Biology
1994 Doctoral Degree Ph.D
CAREER/EMPLOYMENT and RESEARCH EXPERIENCES
11987-1990 B.S. Training in Clinical Immunology. University of Bologna, Italy
1990-1993 Ph.D Student Training in microbiology and applied microbiology. University of Ferrara, Italy. Research activity. Inhibition of HIV-1 replication by tat transdominant negative mutants using retroviral-vector
1993-1994 PhD Fellow. University of Pittsburgh, School of Medicine. Pittsburgh Pa. (USA). Research activity. Development of replication-defective Herpes simplex virus vectors (HSV-1)
1994-1998 Research Associate. University of Pittsburgh, School of Medicine. Pittsburgh Pa. (USA). Research activity. Development of replication-defective Herpes simplex virus vectors (HSV-1) for gene transfer in vivo and their application in animal models
1998-2000 Staff Scientist, Project Leader, HSR- TIGET, Istituto Scientifico San Raffaele, Milan, Italy. Research activity. Molecular analysis of behavior and neurological diseases by gene transfer into neurons with Herpes simplex vector.
2000-2014 Assistant Professor (University Researcher). University of Ferrara. Research activity. Use of HSV-1 vectors for gene transfer in vivo. Gene therapy approaches. Teaching duties on Microbiology and Viral Gene Therapy
2014- 2022 Associate Professor, MED07. University of Ferrara. Research activity on vaccines and basic research on HSV and neurodegeneration. Viral vectors gene therapy and CRISPR/Cas gene editing technology for genetic diseases. Antimicrobial activity for human pathogens and antimicrobial activity for phytopathogens; formulation and evaluation of the antimicrobial activity of synthetic molecules and natural and biological compounds with analysis of the cellular pathways involved. Teaching duties on Microbiology. Applied Microbiology and Viral Gene Therapy
01/02/2022-present Full Professor, MED07. University of Ferrara
Teaching activities in Microbiology, Applied Microbiology and Virology. The research work is mainly focused on the field of virology with particular interest on the Herpes simplex virus, pathogenesis, virus-host interaction, manipulation and development of herpes vectors and their application in gene therapy and vaccines. Gene editing and CRISPR / Cas9. Antimicrobial activity for human pathogens and antimicrobial activity for phytopathogens; formulation and evaluation of the antimicrobial activity of synthetic molecules and natural and biological compounds with analysis of the cellular pathways involved
RESEARCH EXPERIENCES
1987 - 1990 The research activity began with a three-year internship in the clinical immunology laboratory at the Sant'Orsola and Rizzoli Hospital of the University of Bologna. During this period, she worked on the immune system during aging and on the evaluation of responses to the Hepatitis B vaccine.
1990-1993 She continued her research on an ongoing basis by starting his PhD in Biotechnology at the University of Ferrara where he carried out both basic and applied research in virology, gaining strong experience in virology and molecular / cell biology techniques. During this time, she has been mainly interested in the development of retroviral vectors for anti-HIV therapy.
1993-1998 During the 5 years of research carried out in the United States at the "Department of Molecular Genetics and Biochemistry" at the University of Pittsburgh, Pennsylvania - USA, she focused mainly on the biology of herpes viruses and on the development and use of vectors based on Herpes simplex virus (HSV-1). She developed the first vectors for gene therapy based on the Herpes simplex virus (HSV-1) (Marconi P et al. PNAS 1996).
1998 - 2000 she was Head of the laboratory for the study of herpes vectors and clinical applications at the TIGET in the San Raffaele Hospital - Milan, where she obtained funding from public and private bodies both nationally and internationally such as: Telethon, Istituto Superiore della Health, European Community.
From 1998 - 2000 she was the Laboratory Manager for the study of herpetic vectors and clinical applications at TIGET in the San Raffaele Hospital - Milan, where she obtained funding from public and private bodies both nationally and internationally, such as: Telethon, Istituto Superiore of Health, European Community.
Since 2000 she has carried out and continues her research at the University of Ferrara first as a university researcher then as an associate professor and currently as a full professor. During these years she has obtained funding from public and private entities both nationally and internationally
Her research is mainly based on:
1) on the interactions of Herpes simplex and cellular pathways, in particular in the role that some Herpes simplex type 1 genes have as risk factors in the development of neurodegenerative diseases;
2) on the host's immune response to Herpes simplex and other pathogens;
3) on the development of herpetic vectors and their application:
a) as vaccine vectors,
b) vectors for gene therapy,
c) vectors for cancer therapy;
4) studies natural molecules with antimicrobial activity against human pathogens and phytopathogens;
5) with regard to applied microbiology, she works on the development of a gene editing therapy (CRISPR / Cas) for the treatment of Spinocerebellar Ataxia type 1 and 2 (SCA1 and SCA2).
During these years she has obtained funding from public and private bodies both nationally and internationally
TEACHING EXPERIENCES
AA 2000-2001
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
AA 2001-2002
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
AA 2002/03
• Theoretical and practical classes in the integrate course of Immunology and Cellular Techniques, Faculty of Pharmacy, University of Ferrara.
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara
AA 2003/2004
• Microbiology integrated course of Microbiology and Biochemistry, STP, Faculty of Pharmacy, University of Ferrara
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
AA 2004/2005
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
AA 2005/2006
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara.
AA 2006/2007
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Cellular and Molecular Therapy University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
AA 2007/2008
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Gene therapy and laboratory, University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
AA 2008/2009
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Gene therapy and laboratory, University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
AA 2009/2010
• Microbiology into de integrated course Microbiology and Pathology, Faculty of Pharmacy, University of Ferrara
• Microbiology and Vaccines , CTF, Faculty of Pharmacy, University of Ferrara
AA 2011/2012
• Microbiology and Vaccines , CTF. University of Ferrara
AA 2012/2013
• Microbiology and Vaccines , CTF, University of Ferrara
AA 2013/2014
• Microbiology and Applied Microbiology, CTF, University of Ferrara
AA 2014/2015
• Microbiology and Applied Microbiology, CTF, University of Ferrara
• Molecular Virology and applied biotechnologies integrated course of Molecular Virology and Pharmacologic Biotechnologies, University of Ferrara
AA 2015/2016
• Microbiology and Applied Microbiology, CTF, University of Ferrara
• Molecular Virology and applied biotechnologies integrated course of Molecular Virology and Pharmacologic Biotechnologies, University of Ferrara
AA 2016/2017
• Microbiology and Applied Microbiology, CTF, University of Ferrara
• Microbiology in Biological Science, University of Ferrara
• Molecular Virology and applied biotechnologies integrated course of Molecular Virology and Pharmacologic Biotechnologies, University of Ferrara
GRANTS
Personal Research Grants
• Telethon Grant – TIGET 1998-2000
• ex-60% Università di Ferrara 2001, 2002;
• AIRC - Associazione Italiana per la Ricerca sul Cancro 2002;
• AIRC - Associazione Italiana per la Ricerca sul Cancro 2003;
• FISR – Fondo Integrativo Speciale per la Ricerca, 2001, 2002;
• Istituto Superiore di Sanità (Italian Institute of Health), NATIONAL PROGRAM ON STEM CELLS – 2003 , 2004;
• Istituto Superiore di Sanità (Italian Institute of Health), Vaccine project (ICAV) 2007
• PRIN – 2005
• PRIN – 2007
• PRIN – 2009
• Istituto Superiore di Sanità (Italian Institute of Health), AIDS project 2009
• PRIN – 2015
• ERA-NET Neuron 2016 - ELPIS
• FAR – Fondo di Ateneo
• ACAREF Fundation/AISA
She was involved as principal collaborator in the R. Manservigi’s group on 3 European networks EUROAMP (FP5, 2001-2004) of molecular biology of HSV, THOVLEN (FP6, 2006-2008, www.thovlen.eu), HEVAR (FP6, 2007-2009, www.hevar.eu).
PATENTS
South African Patent Application No. 2015/05392 in the name of Vaxxit Srl.
USE OF REPLICATION DEFICIENT HSV-1 AS A VACCINE VECTOR FOR THE DELIVERY OF HIV-1 TAT ANTIGEN
Pubblications:
11. Riccardo Fontana; Anna Caproni; Mariaconcetta Sicurella; Stefano Manfredini; Anna Baldisserotto; Peggy Marconi*. Effects of flavonoids and phenols from Moringa oleifera Lam. leaf extracts on biofilm processes in Xanthomonas campestris pv. campestris. Plants, 2023, accepted, pending proofreading (*Corresponding Author)
2. Sciabica, S.; Barbari, R.; Fontana, R.; Tafuro, G.; Semenzato, A.; Traini, D.; Silva, D.M.; Reis, L.G.D.; Canilli, L.; Terno, M.; Marconi, P.; Baldisserotto, A.; Vertuani, S.; Manfredini, S. A Safe-by-Design Approach for the Synthesis of a Novel Cross-Linked Hyaluronic Acid with Improved Biological and Physical Properties. Pharmaceuticals 2023, 16, 431. https://doi.org/10.3390/ph16030431 [IF2021=5,215]
3. Riccardo Fontana, Laura Beatrice Mattioli, Giulia Biotti, Roberta Budriesi, Roberto Gotti, Matteo Micucci, Ivan Corazza, Peggy Marconi, Maria Frosini, Stefano Manfredini, Raissa Buzzi, Silvia Vertuani. Magnolia Officinalis L. Bark Extract and Respiratory diseases: from Traditional Chinese Medicine to Western Medicine via Network Target. Phytotherapy Research 2023, IF2021=6,388
4. Riccardo Fontana; Marco Marzola; Mattia Buratto; Giulia Trioschi; Anna Caproni; Chiara Nordi; Cesare Buffone; Beatrice Bandera; Luciano Vogli; Peggy Marconi*. Analysis of Civil Environments Cleaning Services—Microbiological and LCA Analysis after Traditional and Sustainable Procedures. Sustainability 2023, 15(1),696; https://doi.org/10.3390/su15010696 (*Corresponding Author)
5. Mariangela Pappadà, Ottavia Bonuccelli, Mattia Buratto, Riccardo Fontana, Mariaconcetta Sicurella, Anna Caproni, Silvia Fuselli, Andrea Benazzo, Roberto Bertorelli, Veronica De Sanctis, Paolo Cavallerio, Valentina Simioni, Valeria Tugnoli, Francesca Salvatori, Peggy Marconi*. Suppressing gain-of-function proteins via CRISPR/Cas9 system in SCA1 cells. Scientific Reports 12, Article number: 20285 (24 Novembre 2022) (*Corresponding Author)
6. Mariaconcetta Sicurella, Walter Pula, Karolina Musia, Katarzyna Cieślik-Boczula, Maddalena Sguizzato, Agnese Bondi, Markus Drechsler, Leda Montesi, Elisabetta Esposito*, and Peggy Marconi. Ethosomal gel for topical administration of dimethyl fumarate in the treatment of HSV-1 infections. International Journal of Molecular Sciences 2023, 24 [IF2021=6,208]
7. Benedusi M.; Tamburini E.; Sicurella M.; Summa D.; Ferrara F.; Marconi P.; Cervellati F.; Costa S.; Valacchi G. The Lesson Learned from the COVID-19 Pandemic: Can an Active Chemical Be Effective, Safe, Harmless-for-Humans and Low-Cost at a Time? Evidence on Aerosolized Hypochlorous Acid. Int. J. Environ. Res. Public Health 2022, 19, x. DOI: 10.3390/ijerph192013163
8. Charles Joussain; Olivier Le Coz; Andrey Pichugin; Peggy Marconi; Filip Lim; Mariaconcetta Sicurella; Keith Foster; François Giuliano; Alberto L. Epstein; Alejandro Aranda Muñoz. Development and Assessment of Herpes Simplex Virus Type 1 (HSV-1) Amplicon Vectors with Sensory Neuron-Selective Promoters. International Journal of Molecular Sciences 2022, 23(15), 8474 DOI: 10.3390/ijms23158474
9. Riccardo Fontana; Peggy Carla Raffaella Marconi; Antonella Caputo; Vasak B. Gavalyan. Novel Chitosan-Based Schiff Base Compounds: Chemical Characterization and Antimicrobial Activity. Molecules 2022, 27(9), 2740. doi: 10.3390/molecules27092740
10. Riccardo Fontana, Giovanna Macchi, Anna Caproni, Mariaconcetta Sicurella, Mattia Buratto, Francesca Salvatori, Mariangela Pappadà, Stefano Manfredini*, Anna Baldisserotto and Peggy Marconi*. Control of Erwinia amylovora Growth by Moringa oleifera Leaf Extracts: In Vitro and in Planta Effects. Plants 2022, 11, 957.
https://doi.org/10.3390/plants11070957 (*Corresponding Author)
11. Francesco Nicoli, Emmanuel Clave, Kerstin Wanke, Amrei von Braun, Vincent Bondet, Cécile Alanio, Corinne Douay, Margaux Baque, Claire Lependu, Peggy Marconi, Karin Stiasny, Franz X. Heinz, Margot Muetsch, Darragh Duffy, Jacques Boddaert, Delphine Sauce, Antoine Toubert, Urs Karrer, Victor Appay. Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. E BioMedicine 2022 Feb; 76:103852.doi: 10.1016/j.ebiom.2022.103852. Epub 2022 Feb 1
12. Mariaconcetta Sicurella, Maddalena Sguizzato, Paolo Mariani, Alessia Pepe, Anna Baldisserotto, Raissa Buzzi, Nicolas Huang, Fanny Simelière, Sam Burholt, Peggy Marconi*, and Elisabetta Esposito*. Natural polyphenol-containing gels against HSV-1 infection: a comparative study. Nanomaterials 2022, 12(2), 227; (*Corresponding Authors)
13. Fontana, Riccardo; Caproni, Anna; Buzzi, Raissa; Sicurella, Mariaconcetta; Buratto, Mattia; Salvatori, Francesca; Pappadà, Mariangela; Manfredini, Stefano; Baldisserotto, Anna; Marconi, Peggy*. Effects of Moringa Oleifera Leaf Extracts on Xanthomonas campestris pv. campestris. Microorganisms, October 2021, 9(11):2244 (*Corresponding Author)
14. Mariaconcetta Sicurella, Maddalena Sguizzato, Rita Cortesi, Nicolas Huang, Fanny Simelière, Leda Montesi, Peggy Marconi *, Elisabetta Esposito*. Mangiferin loaded smart gels for HSV-1 treatment. Pharmaceutics 2021 Aug 24; 13(9): 1323. (*Corresponding Authors)
15. Gallerani, E., Proietto, D., Dallan, B., Campagnaro M., Pacifico S., Albanese V., Marzola E., Marconi P., Caputo A., Appay V., Gavioli, R., Nicoli, F. Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects. Frontiers in Immunology 2021, 12, 693054
16. Stutte, S., Ruf, J., Kugler, I., Ishikawa-Ankerhold, H., Parzefall, A., Marconi, P., Maeda, T., Kaisho, T., Krug, A., Popper, B., Lauterbach, H., Colonna, M., von Andrian, U., Brocker, T., Type Iinterferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice. Brain, Behavior, and Immunity (2021), https://doi.org/10.1016/j.bbi.2021.04.018
17. Nicoli F., Pacifico S., Gallerani E., Marzola E., Albanese V., Finessi V., Llewellyn-Lacey S., Price D.A., Appay V., Marconi P., Guerrini R., Caputo A., Gavioli R. Use of a novel peptide welding technology platform for the development of B- and T-cell epitope-based vaccines. Vaccines 2021, 9(5), 526. doi: 10.3390/vaccines9050526
18. Caputo A. and Marconi P. Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors. Vaccines 2021
19. Nicoli F., Solis-Soto M., Paudel D., Marconi P., Gavioli R., Appay V., Caputo A. Age-related decline of the novo T cell responsiveness as cause of COVID-19 severity. GeroScience 2020 PMID: 32583231
20. Pergolizzi S., Marino A., Capillo G., Aragona M., Marconi P., Lauriano E. R. (2020). Expression of Langerin/CD 207 and α-smooth muscle actin in ex vivo rabbit corneal keratitis model. TISSUE & CELL, vol. 66, p. 101384, ISSN: 0040-8166, doi: 10.1016/j.tice.2020.101384
21. Nicoli F, Mantelli B, Gallerani E, Telatin V, Bonazzi I, Marconi P, Gavioli R, Gabrielli L, Lazzarotto T, Barzon L, Palù G, Caputo A. HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy. Vaccines (Basel). 2020 Jan 14;8(1). pii: E26. doi: 10.3390/vaccines8010026.
22. Sutter SO, Marconi P, Meier AF. Herpes Simplex Virus Growth, Preparation, and Assay. Methods Mol Biol. 2020; 2060:57-72. doi: 10.1007/978-1-4939-9814-2_3.
23. Marino A., Pergolizzi S., Cimino F., Lauriano E.R., Speciale A., D'Angelo V., Sicurella M, Argnani R., Manservigi R, Marconi P.*. Role of Herpes simplex envelope glycoprotein B and toll-like receptor 2 in ocular inflammation: an ex vivo organotypic rabbit corneal model. Viruses 2019, 11(9),819; (*Corresponding Authors)
24. Mancuso R, Sicurella M, Agostini S, Marconi P, Clerici M. Herpes simplex virus type 1 and Alzheimer's disease: link and potential impact on treatment. Expert Rev Anti Infect Ther 2019:1-17.
25. Joussain C, Le Coz O, Pichugin A, Marconi P, Lim F, Sicurella M, Salonia A, Montorsi F, Wandosell F, Foster K, et al: Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons. Toxins (Basel) 2019, 11. DOI: 10.3390/toxins11020123
26. Wagner, A.O., Friedrich, V., Barthels, C., Marconi, P., Blutke, A., Brombacher, F., Brocker, T. Strain specific maturation of Dendritic cells and production of IL-1β controls CD40-driven colitis PLoSONE 2019, doi: 10.1371/journal.pone.0210998
27. Ferrari, D., Idzko, M., Müller, T., Manservigi, R., Marconi, P. Purinergic Signaling: A New Pharmacological Target Against Viruses? Trends in Pharmacological Sciences 2018 DOI: 10. 1016/j.tips.2018.09.004 EID: 2-s2.0-85054135111
28. Brun P., Qesari M., Marconi P.C., Kotsafti A., Porzionato A., Machi V., Schwendener R. A., Palù G., Giron M.C., Scarpa M., Calistri A., Castagliuolo I. Herpes Simplex Virus Type 1 Infects Enteric Neurons and Triggers Gut Dysfunction via Macrophage Recruitment. Frontiers in Cellular and Infection Microbiology. Frontiers in Cellular and Infection Microbiology 2018: doi103389/fcimb.2018.00074.
29. Barthels, C; Ogrinc, A; Steyer, V; Meier, S; Simon, F; Wimmer, M; Blutke, A; Straub, T; Zimber-Strobl, U; Lutgens, E; Marconi, P; Ohnmacht, C; Garzetti, D; Stecher, B; Brocker, T (2017). CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis. DOI:10.1038/ncomms14715. In NATURE COMMUNICATIONS - ISSN:2041-1723 vol. 8
30. Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine. 2016 Apr 27;34(19):2216-24.
31. Cornel Fraefel, Peggy Marconi, Alberto L. Epstein. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors for gene transfer and gene therapy. Neuronal Cell Death: Methods and Protocols – Chapters Edited Springer Science + Bussiness Media Humana Press, NewYork USA. 2015
32. Peggy Marconi, Cornel Fraefel, Alberto L. Epstein. Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy. Neuronal Cell Death: Methods and Protocols – Chapters Edited Springer Science + Bussiness Media Humana Press, NewYork USA. 2015
33. Mariaconcetta Sicurella, Francesco Nicoli, Eleonora Gallerani, Ilaria Volpi, Elena Berto, Valentina Finessi, Federica Destro, Roberto Manservigi, Aurelio Cafaro, Barbara Ensoli, Antonella Caputo, Riccardo Gavioli, Peggy C. Marconi*. An attenuated Herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLOS ONE 2014, Jul 17; 9 (7): e100844. (*Corresponding Author)
34. P. Marconi*, R. Manservigi (2014). Herpes Simplex Virus Growth, Preparation and Assay. Herpes Simplex Virus in Methods in Molecular Biology, Volume 1144, pp 19-29. Springer Science + Bussiness Media Humana Press, NewYork USA, 2014 (*Corresponding Author)
35. Nicoli F, Finessi V, Sicurella M, Rizzotto L. Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, Gavioli R. The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. PLOS ONE November 2013. Vol. 11: e77746
36. Cortesi R., Ravani L., Rinaldi F., Marconi P., Drechsler M., Manservigi M., Argnani R., Menegatti E., Esposito E., Manservigi R. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: A preliminary study as possible vaccine against genital herpes. International Journal of Pharmaceutics 2013. Vol. 440: 229-237
37. Katrin Nopora, Caroline A. Bernhard, Christine Ried, Alejandro A. Castello, Kenneth M. Murphy, Peggy Marconi, Ulrich Koszinowski and Thomas Brocker. MHC class I cross-presentation by dendritic cells counteracts viral immune evasion. Frontiers in Immunology. November 2012. Volume 3, Article 348. doi: 10.3389/fimmu.2012.00348
38. Argnani R, Marconi P, Volpi I, Bolanos E, Carro E, Ried C, Santamaria E, Pourchet A, Epstein A.L, Brocker T, Corrales F.J, Manservigi R, Goicoechea I, Foschini M, Hernandez-Alcoceba R. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver International 2011: 1542-1553
39. Mattoli F., Tiribuzi R., D’Angelo F., Di Girolamo I., Quattrocelli M., Montesano S., Crispoltoni L., Oikonomou V., Cusella De Angelis M. G., Marconi P., Orlacchio A., Sampaolesi M., Martino S. and Orlacchio A. Development of a New Tool for 3D Modeling for Regenerative Medicine. International Journal of Biomedical Imaging. 2011, Article ID 236854, 13 pages
40. Fraefel C, Marconi P, Epstein AL. Herpes Simplex Virus Type 1-Derived Recombinant and Amplicon Vectors. Methods Mol. Biol. 2011: 737:303-343
41. Edelman SL, Marconi P, Brocker T. Peripheral T cells re-enter the thymus and interfere with central tolerance induction. J Immunol. 2011 May 15; 186 (10): 5612-9. Epub 2011 Apr 6
42. Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P, Marzola A, Mora GN, Fabene PF, Simonato M: Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 2011.
43. Marconi P, Manservigi R, Epstein AL: HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel 2010, 13:169-183.
44. Manservigi R, Argnani R, Marconi P*: HSV Recombinant Vectors for Gene Therapy. Open Virol J 2010, 4:123-156. (*Corresponding Author)
45. Gruber A, Cannarile MA, Cheminay C, Ried C, Marconi P, Hacker G, Brocker T: Parenchymal cells critically curtail cytotoxic T-cell responses by inducing Bim-mediated apoptosis. Eur J Immunol 2010, 40:966-975.
46. Foka P, Pourchet A, Hernandez-Alcoceba R, Doumba PP, Pissas G, Kouvatsis V, Dalagiorgou G, Kazazi D, Marconi P, Foschini M, et al.: Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J Gene Med 2010, 12:956-967.
47. Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, Navarro Mora G, Osculati F, Berto E, Marconi P, Marzola A, et al.: Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 2010, 7:81.
48. Santamaria E, Mora MI, Carro-Roldan E, Molina M, Fernandez-Irigoyen J, Marconi P, Manservigi R, Greco A, Epstein AL, Prieto J, et al.: Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft. J Proteomics 2009, 73:153-160.
49. Paradiso B,° Marconi P,° Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Navarro Mora G, et al.: Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A 2009, 106:7191-7196. (°The authors contributed equally to this paper)
50. Marconi P*, Argnani R, Epstein AL, Manservigi R: HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol 2009, 655:118-144. (*Corresponding Author)
51. Marconi P., Argnani R., Epstein A. L., Manservigi R. (2009). HSV as a vector in vaccine development and gene therapy. Pharmaceutical Biotechnology. p. 118-144, Carlos A. Guzman & Giora Feuerstein. Landes Biosci, ISBN/ISSN: 978-1-4419-1131-5.
52. Marconi P*, Argnani R, Berto E, Epstein AL, Manservigi R: HSV as a vector in vaccine development and gene therapy. Hum Vaccine 2008, 4:91-105 (*Corresponding Author)
53. Luckashenak N, Schroeder S, Endt K, Schmidt D, Mahnke K, Bachmann MF, Marconi P, Deeg CA, Brocker T: Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008, 28:521-532.
54. Dresch C, Edelmann SL, Marconi P, Brocker T: Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008, 181:4495-4506.
55. Werner-Klein M, Dresch C, Marconi P, Brocker T: Transcriptional targeting of B cells for induction of peripheral CD8 T cell tolerance. J Immunol 2007, 178:7738-7746.
56. Furlan R, Bergami A, Brambilla E, Butti E, De Simoni MG, Campagnoli M, Marconi P, Comi G, Martino G: HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2007, 14:93-98.
57. Fiorentini S, ° Marconi P, ° Avolio M, Marini E, Garrafa E, Caracciolo S, Rossi D, Bozac A, Becker PD, Gentili F, et al.: Replication-deficient mutant Herpes Simplex Virus-1 targets professional antigen presenting cells and induces efficient CD4+ T helper responses. Microbes and Infection 2007, 9:988-996. (°The authors contributed equally to this paper)
58. Berto E, Bozac A, Volpi I, Lanzoni I, Vasquez F, Melara N, Manservigi R, Marconi P*: Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. Cancer Gene Ther 2007, 14:791-801. (*Corresponding Authors)
59. Manservigi R., Argnani R., Marconi P., Epstein A (2007). Herpesvirus-based vectors for gene transfer, gene therapy and the development of novel vaccines. Virus Expression Vectors 2007. p. 205-246, Kerala: Kathleen L. Hefferon
60. Fiorentini S, Becker PD, Marini E, Marconi P, Avolio M, Tosti G, Link C, Manservigi R, Guzman CA, Caruso A: HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens. Viral Immunol 2006, 19:177-188.
61. Bozac A, Berto E, Vasquez F, Grandi P, Caputo A, Manservigi R, Ensoli B, Marconi P*: Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine 2006, 24:7148-7158. (*Corresponding Authors)
62. Martino S, ° Marconi P,° Tancini B, Dolcetta D, De Angelis MG, Montanucci P, Bregola G, Sandhoff K, Bordignon C, Emiliani C, et al.: A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 2005, 14:2113-2123. (°The authors contributed equally to this paper)
63. Marconi P, Zucchini S, Berto E, Bozac A, Paradiso B, Bregola G, Grassi C, Volpi I, Argnani R, Marzola A, et al.: Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo. Gene Ther 2005, 12:559-569.
64. Lauterbach H, Ried C, Epstein AL, Marconi P, Brocker T: Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 2005, 86:2401-2410.
65. Epstein AL, Marconi P, Argnani R, Manservigi R: HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther 2005, 5:445-458.
66. Berto E, Bozac A, Marconi P*. Development and application of replication-incompetent HSV-1-based vectors. Gene Ther 2005, 12 Suppl 1:S98-102. (*Corresponding Authors)
67. Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P, Manservigi R, Gariglio M, Landolfo S: The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res 2004, 293:331-345.
68. Lauterbach H, Kerksiek KM, Busch DH, Berto E, Bozac A, Mavromara P, Manservigi R, Epstein AL, Marconi P,^ Brocker T^: Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 2004, 78:4020-4028. (^Corresponding Authors and Shared senior authorship)
69. Argnani R, Boccafogli L, Marconi PC, Manservigi R: Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Ther 2004, 11:1087-1098.
70. Furlan R, Pluchino S, Marconi PC, Martino G: Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. Methods Mol Biol 2003, 215:279-289.
71. Goins WF, Marconi P, Krisky D, Wolfe D, Glorioso JC, Ramakrishnan R, Fink DJ: Construction of replication-defective herpes simplex virus vectors. Curr Protoc Hum Genet 2002, Chapter 12:Unit 12 11.
72. Ruffini F, Furlan R, Poliani PL, Brambilla E, Marconi PC, Bergami A, Desina G, Glorioso JC, Comi G, Martino G: Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2001, 8:1207-1213.
73. Poliani PL, Brok H, Furlan R, Ruffini F, Bergami A, Desina G, Marconi PC, Rovaris M, Uccelli A, Glorioso JC, et al.: Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001, 12:905-920.
74. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L, Glorioso JC, Comi G, Martino G: Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther 2001, 8:13-19.
75. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, et al.: Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001, 167:1821-1829.
76. Furlan R, Poliani P.L., Bergami A., Ruffini F., Brambilla E., Marconi P., Comi G., Martino G.. Immunogene therapy for autoimmune demyelination In: Brain Diseases: Therapeutic Strategies and Repair. Immune-mediated brain injuries. Miller A., Abramsky O., Compston D., Said G. (Eds.). Martin Dunitz, London. 2001, pp 11.1-11.7.
77. Simonato M, Manservigi R, Marconi P, Glorioso J: Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. Trends Neurosci 2000, 23:183-190.
78. Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, Yoshimine T, Cohen JB, Glorioso JC: HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther 2000, 7:1483-1490.
79. Martino G, Poliani PL, Marconi PC, Comi G, Furlan R: Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors. Gene Ther 2000, 7:1087-1093.
80. Martino G, Poliani PL, Furlan R, Marconi P, Glorioso JC, Adorini L, Comi G: Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J Neuroimmunol 2000, 107:184-190.
81. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF, Cohen JB, Glorioso JC: Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther 2000, 1:71-81.
82. Gomez-Navarro J, Contreras JL, Arafat W, Jiang XL, Krisky D, Oligino T, Marconi P, Hubbard B, Glorioso JC, Curiel DT, et al.: Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 2000, 7:43-52.
83. Martino G., Furlan R., Poliani P.L., Bergami A., Desina G., Comi G., Marconi P. Gene Therapy: a possible future option for multiple sclerosis. In: Advances in Multiple Sclerosis. Clinical Research and Therapy. S.Fredrikson and H. Link eds.. Martin Dunitz, London, 1999: 125-136;
84. Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC: Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 1999, 159:34-46.
85. Simonato M, Marconi P, Glorioso J, Manservigi R: Molecular analysis of behavior by gene transfer into neurons with herpes simplex vectors. Brain Res 1999, 835:37-45.
86. Marconi P, Simonato M, Zucchini S, Bregola G, Argnani R, Krisky D, Glorioso JC, Manservigi R: Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther 1999, 6:904-912.
87. Laquerre S., Goins W.F., Moriuchi S., Oligino T., Krisky D.M., Marconi P., Soares M.K., Cohen J.B., Fink D.J., and Glorioso J.C. Gene transfer tool: Herpes simplex virus vectors. In The Development of Human Gene Therapy. Theodore Friedmann (ed.), Cold Spring Harbor Laboratory Press, NY, 1998.
88. Goins, W.F., Marconi P, Krisky, D., Ramakrishnan, R., Fink, D.J., and Glorioso, J.C. Construction of Replication Defective Herpes Simplex Virus Vectors. In Current Protocols in Human Genetics, E. Nabel (ed.), John Wiley Sons, Inc., 1997.
89. Goins W.F., Oligino T., Krisky D., Marconi P, Poliani P.L., Ramakrishnan R., Fink D.J., Glorioso J.C..Herpes Simplex Virus mediated gene transfer to neurons. in Concepts in Gene Therapy. Michael Strauss M. and Barranger J. A. (eds.). Berlin; New York: de Gruyter, 1997.
90. Oligino T., Krisky D., Marconi P., Fink D.J., and Glorioso, J.C. Herpes simplex gene therapy vectors for the treatment of cancer. Chapter in: Advances in Neuro-Oncology, M Walker and P. Korblith (eds.) Future Publishing Company, Inc. Ny. 1997.
91. Glorioso J.C., Krisky D., Marconi P., Oligino T., S. Ghivizzani, P.D. Robbins, M. Schmidt, W.F. Goins, and C. Evans: Progress in development of herpes simplex virus gene vectors for the treatment of rheumatoid arthritis, Chapter in Advanced Drug Delivery Reviews, B.L. Davidson (ed.) Elsevier, 1997.
92. Huard, J., Krisky D., Oligino T., Marconi P., Day C.S., Watkins, S.C., Glorioso, J.C. Gene transfer to muscle using herpes simplex virus-based vectors. Chapter in Concepts in gene therapy. M.Strauss and J. Barranger (eds.) Walter De Gruyrter and Co. Berlin, 1997.
93. Huard J., Goins W.F., Akkaraju G.R., Krisky D., Oligino T., Marconi P, and Glorioso J.C. Gene transfer to muscle and spinal cord using herpes simplex virus-based vectors. In Gene Therapy Technologies and Regulations from Laboratory to Clinic, A. Meager (ed.), John Wiley & Sons, Inc., 1997.
94. Krisky, D., Marconi P, Goins, W.F., and Glorioso, J.C. Development of Replication-Defective Herpes Simplex Virus Vectors. Chapter in Methods in Molecular Medicine, Gene Therapy Protocols, P.Robbins (ed.) Humana Press Inc. Totowa, N.J. 1996.
95. Wang M, Rancourt C, Navarro JG, Krisky D, Marconi P, Oligino T, Alvarez RD, Siegal GP, Glorioso JC, Curiel DT: High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol Oncol 1998, 71:278-287.
96. van Deutekom JC, Floyd SS, Booth DK, Oligino T, Krisky D, Marconi P, Glorioso JC, Huard J: Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscul Disord 1998, 8:135-148.
97. Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J, Glorioso JC: Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 1998, 58:5731-5737.
98. Kuklin NA, Daheshia M, Marconi PC, Krisky DM, Rouse RJ, Glorioso JC, Manican E, Rouse BT: Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology 1998, 240:245-253.
99. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 1998, 5:1593-1603.
100. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB, Watkins SC, Glorioso JC: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 1998, 5:1517-1530.
101. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso JC: Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 1997, 4:1120-1125.
102. Huard J, Krisky D, Oligino T, Marconi P, Day CS, Watkins SC, Glorioso JC: Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord 1997, 7:299-313.
103. Goins WF, Krisky D, Marconi P, Oligino T, Ramakrishnan R, Poliani PL, Fink DJ, Glorioso JC: Herpes simplex virus vectors for gene transfer to the nervous system. J Neurovirol 1997, 3 Suppl 1:S80-88.
104. Glorioso JC, Goins WF, Schmidt MC, Oligino T, Krisky DM, Marconi PC, Cavalcoli JD, Ramakrishnan R, Poliani PL, Fink DJ: Engineering herpes simplex virus vectors for human gene therapy. Adv Pharmacol 1997, 40:103-136.
105. Evans C, Goins WF, Schmidt MC, Robbins PD, Ghivizzani SC, Oligino T, Marconi P, Krisky D, Glorioso JC: Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis. Adv Drug Deliv Rev 1997, 27:41-57.
106. Oligino T, Poliani PL, Marconi P, Bender MA, Schmidt MC, Fink DJ, Glorioso JC: In vivo transgene activation from an HSV-based gene therapy vector by GAL4:VP16. Gene Ther 1996, 3:892-899.
107. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF, Fink DJ, Glorioso JC: Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A 1996, 93:11319-11320.
108. Caputo A, Grossi MP, Bozzini R, Rossi C, Betti M, Marconi PC, Barbanti-Brodano G, Balboni PG: Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Ther 1996, 3:235-245.
109. Fink DJ, Ramakrishnan R, Marconi P, Goins WF, Holland TC, Glorioso JC: Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Clin Neurosci 1995, 3:284-291.
110. Grossi MP, Caputo A, Zucchini S, Bozzini R, Marconi PC, Manservigi R, Barbanti-Brodano G, Balboni PG: Molecular approaches to inhibit HIV-1 tat expression and functions. Year Immunol 1993, 7:199-204.
111. Balboni PG, Bozzini R, Zucchini S, Marconi PC, Grossi MP, Caputo A, Manservigi R, Barbanti-Brodano G: Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant. J Med Virol 1993, 41:289-295.
112. Grossi M.P., Caputo A., Zucchini S., Bozzini R., Marconi P.C., Manservigi R., Barbanti-Brodano G., and Balboni P.G. Molecular approaches to inhibit HIV-1 tat expression and functions. In "Generation of Antibodies by Cell and Gene Immortalization" C. Terhorst, F. Malavasi & A. Albertini (eds.), Basel, S. Karger, Year Immunol. vol.7, pp.199-204, 1993.
113. Sabbioni S., Negrini M., Marconi P.C. and Manservigi R. Detection of Herpes simplex virus type-specific antibody with recombinant glycoprotein G. In "European Biotechnology Today. The impact of basic sciences on diagnosis and therapy" F. Malavasi, R. Cortese, and A. Albertini (Eds.). Andover (UK), Intercept Ltd., pp. 235-243, 1992
Peggy C.R. Marconi, Ph.D.
Place of Birth : Caracas, Venezuela
Date of Birth : November 04,1966
Citizenship: Italian
Present position and title: Full Professor, Ph.D.
Full Professor in Microbiology
Department of Chemical and Pharmaceutical Sciences (DipSCF)
University of Ferrara
Via Fossato di Mortara 64/A, 44121 Ferrara, Italy
Phone number: +39-0532-455381
e-mail: mcy@unife.it
ORCID link http://orcid.org/0000-0003-3488-0491
Scopus Author ID: 7004929498
Language skills: Spanish, Italian, English, French.
EDUCATION
1985/1990 University of Bologna, Italy; BS, , Biological Sciences 110/110 full marks cum laude
1990/1994 University of Ferrara, Italy; Ph.D student, Biothecnologies
1993/1994 University of Pittsburgh, Ph.D fellow, Virology and Molecular Biology
1994 Doctoral Degree Ph.D
CAREER/EMPLOYMENT and RESEARCH EXPERIENCES
11987-1990 B.S. Training in Clinical Immunology. University of Bologna, Italy
1990-1993 Ph.D Student Training in microbiology and applied microbiology. University of Ferrara, Italy. Research activity. Inhibition of HIV-1 replication by tat transdominant negative mutants using retroviral-vector
1993-1994 PhD Fellow. University of Pittsburgh, School of Medicine. Pittsburgh Pa. (USA). Research activity. Development of replication-defective Herpes simplex virus vectors (HSV-1)
1994-1998 Research Associate. University of Pittsburgh, School of Medicine. Pittsburgh Pa. (USA). Research activity. Development of replication-defective Herpes simplex virus vectors (HSV-1) for gene transfer in vivo and their application in animal models
1998-2000 Staff Scientist, Project Leader, HSR- TIGET, Istituto Scientifico San Raffaele, Milan, Italy. Research activity. Molecular analysis of behavior and neurological diseases by gene transfer into neurons with Herpes simplex vector.
2000-2014 Assistant Professor (University Researcher). University of Ferrara. Research activity. Use of HSV-1 vectors for gene transfer in vivo. Gene therapy approaches. Teaching duties on Microbiology and Viral Gene Therapy
2014- 2022 Associate Professor, MED07. University of Ferrara. Research activity on vaccines and basic research on HSV and neurodegeneration. Viral vectors gene therapy and CRISPR/Cas gene editing technology for genetic diseases. Antimicrobial activity for human pathogens and antimicrobial activity for phytopathogens; formulation and evaluation of the antimicrobial activity of synthetic molecules and natural and biological compounds with analysis of the cellular pathways involved. Teaching duties on Microbiology. Applied Microbiology and Viral Gene Therapy
01/02/2022-present Full Professor, MED07. University of Ferrara
Teaching activities in Microbiology, Applied Microbiology and Virology. The research work is mainly focused on the field of virology with particular interest on the Herpes simplex virus, pathogenesis, virus-host interaction, manipulation and development of herpes vectors and their application in gene therapy and vaccines. Gene editing and CRISPR / Cas9. Antimicrobial activity for human pathogens and antimicrobial activity for phytopathogens; formulation and evaluation of the antimicrobial activity of synthetic molecules and natural and biological compounds with analysis of the cellular pathways involved
RESEARCH EXPERIENCES
1987 - 1990 The research activity began with a three-year internship in the clinical immunology laboratory at the Sant'Orsola and Rizzoli Hospital of the University of Bologna. During this period, she worked on the immune system during aging and on the evaluation of responses to the Hepatitis B vaccine.
1990-1993 She continued her research on an ongoing basis by starting his PhD in Biotechnology at the University of Ferrara where he carried out both basic and applied research in virology, gaining strong experience in virology and molecular / cell biology techniques. During this time, she has been mainly interested in the development of retroviral vectors for anti-HIV therapy.
1993-1998 During the 5 years of research carried out in the United States at the "Department of Molecular Genetics and Biochemistry" at the University of Pittsburgh, Pennsylvania - USA, she focused mainly on the biology of herpes viruses and on the development and use of vectors based on Herpes simplex virus (HSV-1). She developed the first vectors for gene therapy based on the Herpes simplex virus (HSV-1) (Marconi P et al. PNAS 1996).
1998 - 2000 she was Head of the laboratory for the study of herpes vectors and clinical applications at the TIGET in the San Raffaele Hospital - Milan, where she obtained funding from public and private bodies both nationally and internationally such as: Telethon, Istituto Superiore della Health, European Community.
From 1998 - 2000 she was the Laboratory Manager for the study of herpetic vectors and clinical applications at TIGET in the San Raffaele Hospital - Milan, where she obtained funding from public and private bodies both nationally and internationally, such as: Telethon, Istituto Superiore of Health, European Community.
Since 2000 she has carried out and continues her research at the University of Ferrara first as a university researcher then as an associate professor and currently as a full professor. During these years she has obtained funding from public and private entities both nationally and internationally
Her research is mainly based on:
1) on the interactions of Herpes simplex and cellular pathways, in particular in the role that some Herpes simplex type 1 genes have as risk factors in the development of neurodegenerative diseases;
2) on the host's immune response to Herpes simplex and other pathogens;
3) on the development of herpetic vectors and their application:
a) as vaccine vectors,
b) vectors for gene therapy,
c) vectors for cancer therapy;
4) studies natural molecules with antimicrobial activity against human pathogens and phytopathogens;
5) with regard to applied microbiology, she works on the development of a gene editing therapy (CRISPR / Cas) for the treatment of Spinocerebellar Ataxia type 1 and 2 (SCA1 and SCA2).
During these years she has obtained funding from public and private bodies both nationally and internationally
TEACHING EXPERIENCES
AA 2000-2001
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
AA 2001-2002
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
AA 2002/03
• Theoretical and practical classes in the integrate course of Immunology and Cellular Techniques, Faculty of Pharmacy, University of Ferrara.
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara
AA 2003/2004
• Microbiology integrated course of Microbiology and Biochemistry, STP, Faculty of Pharmacy, University of Ferrara
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
AA 2004/2005
• Applied Microbiology, CTF, Faculty of Pharmacy, University of Ferrara.
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
AA 2005/2006
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara.
AA 2006/2007
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Cellular and Molecular Therapy University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
AA 2007/2008
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Gene therapy and laboratory, University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
AA 2008/2009
• Applied Microbiology and advance laboratories on Cellular Techniques, Faculty of Pharmacy, University of Ferrara
• Gene therapy and laboratory, University of Ferrara
• Applied and industrial Microbiology integrated course, CTF, Faculty of Pharmacy, University of Ferrara
• Microbiology of Functional Products, STP, Faculty of Pharmacy, University of Ferrara
AA 2009/2010
• Microbiology into de integrated course Microbiology and Pathology, Faculty of Pharmacy, University of Ferrara
• Microbiology and Vaccines , CTF, Faculty of Pharmacy, University of Ferrara
AA 2011/2012
• Microbiology and Vaccines , CTF. University of Ferrara
AA 2012/2013
• Microbiology and Vaccines , CTF, University of Ferrara
AA 2013/2014
• Microbiology and Applied Microbiology, CTF, University of Ferrara
AA 2014/2015
• Microbiology and Applied Microbiology, CTF, University of Ferrara
• Molecular Virology and applied biotechnologies integrated course of Molecular Virology and Pharmacologic Biotechnologies, University of Ferrara
AA 2015/2016
• Microbiology and Applied Microbiology, CTF, University of Ferrara
• Molecular Virology and applied biotechnologies integrated course of Molecular Virology and Pharmacologic Biotechnologies, University of Ferrara
AA 2016/2017
• Microbiology and Applied Microbiology, CTF, University of Ferrara
• Microbiology in Biological Science, University of Ferrara
• Molecular Virology and applied biotechnologies integrated course of Molecular Virology and Pharmacologic Biotechnologies, University of Ferrara
GRANTS
Personal Research Grants
• Telethon Grant – TIGET 1998-2000
• ex-60% Università di Ferrara 2001, 2002;
• AIRC - Associazione Italiana per la Ricerca sul Cancro 2002;
• AIRC - Associazione Italiana per la Ricerca sul Cancro 2003;
• FISR – Fondo Integrativo Speciale per la Ricerca, 2001, 2002;
• Istituto Superiore di Sanità (Italian Institute of Health), NATIONAL PROGRAM ON STEM CELLS – 2003 , 2004;
• Istituto Superiore di Sanità (Italian Institute of Health), Vaccine project (ICAV) 2007
• PRIN – 2005
• PRIN – 2007
• PRIN – 2009
• Istituto Superiore di Sanità (Italian Institute of Health), AIDS project 2009
• PRIN – 2015
• ERA-NET Neuron 2016 - ELPIS
• FAR – Fondo di Ateneo
• ACAREF Fundation/AISA
She was involved as principal collaborator in the R. Manservigi’s group on 3 European networks EUROAMP (FP5, 2001-2004) of molecular biology of HSV, THOVLEN (FP6, 2006-2008, www.thovlen.eu), HEVAR (FP6, 2007-2009, www.hevar.eu).
PATENTS
South African Patent Application No. 2015/05392 in the name of Vaxxit Srl.
USE OF REPLICATION DEFICIENT HSV-1 AS A VACCINE VECTOR FOR THE DELIVERY OF HIV-1 TAT ANTIGEN
Pubblications:
11. Riccardo Fontana; Anna Caproni; Mariaconcetta Sicurella; Stefano Manfredini; Anna Baldisserotto; Peggy Marconi*. Effects of flavonoids and phenols from Moringa oleifera Lam. leaf extracts on biofilm processes in Xanthomonas campestris pv. campestris. Plants, 2023, accepted, pending proofreading (*Corresponding Author)
2. Sciabica, S.; Barbari, R.; Fontana, R.; Tafuro, G.; Semenzato, A.; Traini, D.; Silva, D.M.; Reis, L.G.D.; Canilli, L.; Terno, M.; Marconi, P.; Baldisserotto, A.; Vertuani, S.; Manfredini, S. A Safe-by-Design Approach for the Synthesis of a Novel Cross-Linked Hyaluronic Acid with Improved Biological and Physical Properties. Pharmaceuticals 2023, 16, 431. https://doi.org/10.3390/ph16030431 [IF2021=5,215]
3. Riccardo Fontana, Laura Beatrice Mattioli, Giulia Biotti, Roberta Budriesi, Roberto Gotti, Matteo Micucci, Ivan Corazza, Peggy Marconi, Maria Frosini, Stefano Manfredini, Raissa Buzzi, Silvia Vertuani. Magnolia Officinalis L. Bark Extract and Respiratory diseases: from Traditional Chinese Medicine to Western Medicine via Network Target. Phytotherapy Research 2023, IF2021=6,388
4. Riccardo Fontana; Marco Marzola; Mattia Buratto; Giulia Trioschi; Anna Caproni; Chiara Nordi; Cesare Buffone; Beatrice Bandera; Luciano Vogli; Peggy Marconi*. Analysis of Civil Environments Cleaning Services—Microbiological and LCA Analysis after Traditional and Sustainable Procedures. Sustainability 2023, 15(1),696; https://doi.org/10.3390/su15010696 (*Corresponding Author)
5. Mariangela Pappadà, Ottavia Bonuccelli, Mattia Buratto, Riccardo Fontana, Mariaconcetta Sicurella, Anna Caproni, Silvia Fuselli, Andrea Benazzo, Roberto Bertorelli, Veronica De Sanctis, Paolo Cavallerio, Valentina Simioni, Valeria Tugnoli, Francesca Salvatori, Peggy Marconi*. Suppressing gain-of-function proteins via CRISPR/Cas9 system in SCA1 cells. Scientific Reports 12, Article number: 20285 (24 Novembre 2022) (*Corresponding Author)
6. Mariaconcetta Sicurella, Walter Pula, Karolina Musia, Katarzyna Cieślik-Boczula, Maddalena Sguizzato, Agnese Bondi, Markus Drechsler, Leda Montesi, Elisabetta Esposito*, and Peggy Marconi. Ethosomal gel for topical administration of dimethyl fumarate in the treatment of HSV-1 infections. International Journal of Molecular Sciences 2023, 24 [IF2021=6,208]
7. Benedusi M.; Tamburini E.; Sicurella M.; Summa D.; Ferrara F.; Marconi P.; Cervellati F.; Costa S.; Valacchi G. The Lesson Learned from the COVID-19 Pandemic: Can an Active Chemical Be Effective, Safe, Harmless-for-Humans and Low-Cost at a Time? Evidence on Aerosolized Hypochlorous Acid. Int. J. Environ. Res. Public Health 2022, 19, x. DOI: 10.3390/ijerph192013163
8. Charles Joussain; Olivier Le Coz; Andrey Pichugin; Peggy Marconi; Filip Lim; Mariaconcetta Sicurella; Keith Foster; François Giuliano; Alberto L. Epstein; Alejandro Aranda Muñoz. Development and Assessment of Herpes Simplex Virus Type 1 (HSV-1) Amplicon Vectors with Sensory Neuron-Selective Promoters. International Journal of Molecular Sciences 2022, 23(15), 8474 DOI: 10.3390/ijms23158474
9. Riccardo Fontana; Peggy Carla Raffaella Marconi; Antonella Caputo; Vasak B. Gavalyan. Novel Chitosan-Based Schiff Base Compounds: Chemical Characterization and Antimicrobial Activity. Molecules 2022, 27(9), 2740. doi: 10.3390/molecules27092740
10. Riccardo Fontana, Giovanna Macchi, Anna Caproni, Mariaconcetta Sicurella, Mattia Buratto, Francesca Salvatori, Mariangela Pappadà, Stefano Manfredini*, Anna Baldisserotto and Peggy Marconi*. Control of Erwinia amylovora Growth by Moringa oleifera Leaf Extracts: In Vitro and in Planta Effects. Plants 2022, 11, 957.
https://doi.org/10.3390/plants11070957 (*Corresponding Author)
11. Francesco Nicoli, Emmanuel Clave, Kerstin Wanke, Amrei von Braun, Vincent Bondet, Cécile Alanio, Corinne Douay, Margaux Baque, Claire Lependu, Peggy Marconi, Karin Stiasny, Franz X. Heinz, Margot Muetsch, Darragh Duffy, Jacques Boddaert, Delphine Sauce, Antoine Toubert, Urs Karrer, Victor Appay. Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. E BioMedicine 2022 Feb; 76:103852.doi: 10.1016/j.ebiom.2022.103852. Epub 2022 Feb 1
12. Mariaconcetta Sicurella, Maddalena Sguizzato, Paolo Mariani, Alessia Pepe, Anna Baldisserotto, Raissa Buzzi, Nicolas Huang, Fanny Simelière, Sam Burholt, Peggy Marconi*, and Elisabetta Esposito*. Natural polyphenol-containing gels against HSV-1 infection: a comparative study. Nanomaterials 2022, 12(2), 227; (*Corresponding Authors)
13. Fontana, Riccardo; Caproni, Anna; Buzzi, Raissa; Sicurella, Mariaconcetta; Buratto, Mattia; Salvatori, Francesca; Pappadà, Mariangela; Manfredini, Stefano; Baldisserotto, Anna; Marconi, Peggy*. Effects of Moringa Oleifera Leaf Extracts on Xanthomonas campestris pv. campestris. Microorganisms, October 2021, 9(11):2244 (*Corresponding Author)
14. Mariaconcetta Sicurella, Maddalena Sguizzato, Rita Cortesi, Nicolas Huang, Fanny Simelière, Leda Montesi, Peggy Marconi *, Elisabetta Esposito*. Mangiferin loaded smart gels for HSV-1 treatment. Pharmaceutics 2021 Aug 24; 13(9): 1323. (*Corresponding Authors)
15. Gallerani, E., Proietto, D., Dallan, B., Campagnaro M., Pacifico S., Albanese V., Marzola E., Marconi P., Caputo A., Appay V., Gavioli, R., Nicoli, F. Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects. Frontiers in Immunology 2021, 12, 693054
16. Stutte, S., Ruf, J., Kugler, I., Ishikawa-Ankerhold, H., Parzefall, A., Marconi, P., Maeda, T., Kaisho, T., Krug, A., Popper, B., Lauterbach, H., Colonna, M., von Andrian, U., Brocker, T., Type Iinterferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice. Brain, Behavior, and Immunity (2021), https://doi.org/10.1016/j.bbi.2021.04.018
17. Nicoli F., Pacifico S., Gallerani E., Marzola E., Albanese V., Finessi V., Llewellyn-Lacey S., Price D.A., Appay V., Marconi P., Guerrini R., Caputo A., Gavioli R. Use of a novel peptide welding technology platform for the development of B- and T-cell epitope-based vaccines. Vaccines 2021, 9(5), 526. doi: 10.3390/vaccines9050526
18. Caputo A. and Marconi P. Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors. Vaccines 2021
19. Nicoli F., Solis-Soto M., Paudel D., Marconi P., Gavioli R., Appay V., Caputo A. Age-related decline of the novo T cell responsiveness as cause of COVID-19 severity. GeroScience 2020 PMID: 32583231
20. Pergolizzi S., Marino A., Capillo G., Aragona M., Marconi P., Lauriano E. R. (2020). Expression of Langerin/CD 207 and α-smooth muscle actin in ex vivo rabbit corneal keratitis model. TISSUE & CELL, vol. 66, p. 101384, ISSN: 0040-8166, doi: 10.1016/j.tice.2020.101384
21. Nicoli F, Mantelli B, Gallerani E, Telatin V, Bonazzi I, Marconi P, Gavioli R, Gabrielli L, Lazzarotto T, Barzon L, Palù G, Caputo A. HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy. Vaccines (Basel). 2020 Jan 14;8(1). pii: E26. doi: 10.3390/vaccines8010026.
22. Sutter SO, Marconi P, Meier AF. Herpes Simplex Virus Growth, Preparation, and Assay. Methods Mol Biol. 2020; 2060:57-72. doi: 10.1007/978-1-4939-9814-2_3.
23. Marino A., Pergolizzi S., Cimino F., Lauriano E.R., Speciale A., D'Angelo V., Sicurella M, Argnani R., Manservigi R, Marconi P.*. Role of Herpes simplex envelope glycoprotein B and toll-like receptor 2 in ocular inflammation: an ex vivo organotypic rabbit corneal model. Viruses 2019, 11(9),819; (*Corresponding Authors)
24. Mancuso R, Sicurella M, Agostini S, Marconi P, Clerici M. Herpes simplex virus type 1 and Alzheimer's disease: link and potential impact on treatment. Expert Rev Anti Infect Ther 2019:1-17.
25. Joussain C, Le Coz O, Pichugin A, Marconi P, Lim F, Sicurella M, Salonia A, Montorsi F, Wandosell F, Foster K, et al: Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons. Toxins (Basel) 2019, 11. DOI: 10.3390/toxins11020123
26. Wagner, A.O., Friedrich, V., Barthels, C., Marconi, P., Blutke, A., Brombacher, F., Brocker, T. Strain specific maturation of Dendritic cells and production of IL-1β controls CD40-driven colitis PLoSONE 2019, doi: 10.1371/journal.pone.0210998
27. Ferrari, D., Idzko, M., Müller, T., Manservigi, R., Marconi, P. Purinergic Signaling: A New Pharmacological Target Against Viruses? Trends in Pharmacological Sciences 2018 DOI: 10. 1016/j.tips.2018.09.004 EID: 2-s2.0-85054135111
28. Brun P., Qesari M., Marconi P.C., Kotsafti A., Porzionato A., Machi V., Schwendener R. A., Palù G., Giron M.C., Scarpa M., Calistri A., Castagliuolo I. Herpes Simplex Virus Type 1 Infects Enteric Neurons and Triggers Gut Dysfunction via Macrophage Recruitment. Frontiers in Cellular and Infection Microbiology. Frontiers in Cellular and Infection Microbiology 2018: doi103389/fcimb.2018.00074.
29. Barthels, C; Ogrinc, A; Steyer, V; Meier, S; Simon, F; Wimmer, M; Blutke, A; Straub, T; Zimber-Strobl, U; Lutgens, E; Marconi, P; Ohnmacht, C; Garzetti, D; Stecher, B; Brocker, T (2017). CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis. DOI:10.1038/ncomms14715. In NATURE COMMUNICATIONS - ISSN:2041-1723 vol. 8
30. Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine. 2016 Apr 27;34(19):2216-24.
31. Cornel Fraefel, Peggy Marconi, Alberto L. Epstein. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors for gene transfer and gene therapy. Neuronal Cell Death: Methods and Protocols – Chapters Edited Springer Science + Bussiness Media Humana Press, NewYork USA. 2015
32. Peggy Marconi, Cornel Fraefel, Alberto L. Epstein. Herpes simplex virus type 1 (HSV-1)-derived recombinant vectors for gene transfer and gene therapy. Neuronal Cell Death: Methods and Protocols – Chapters Edited Springer Science + Bussiness Media Humana Press, NewYork USA. 2015
33. Mariaconcetta Sicurella, Francesco Nicoli, Eleonora Gallerani, Ilaria Volpi, Elena Berto, Valentina Finessi, Federica Destro, Roberto Manservigi, Aurelio Cafaro, Barbara Ensoli, Antonella Caputo, Riccardo Gavioli, Peggy C. Marconi*. An attenuated Herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLOS ONE 2014, Jul 17; 9 (7): e100844. (*Corresponding Author)
34. P. Marconi*, R. Manservigi (2014). Herpes Simplex Virus Growth, Preparation and Assay. Herpes Simplex Virus in Methods in Molecular Biology, Volume 1144, pp 19-29. Springer Science + Bussiness Media Humana Press, NewYork USA, 2014 (*Corresponding Author)
35. Nicoli F, Finessi V, Sicurella M, Rizzotto L. Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, Gavioli R. The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. PLOS ONE November 2013. Vol. 11: e77746
36. Cortesi R., Ravani L., Rinaldi F., Marconi P., Drechsler M., Manservigi M., Argnani R., Menegatti E., Esposito E., Manservigi R. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: A preliminary study as possible vaccine against genital herpes. International Journal of Pharmaceutics 2013. Vol. 440: 229-237
37. Katrin Nopora, Caroline A. Bernhard, Christine Ried, Alejandro A. Castello, Kenneth M. Murphy, Peggy Marconi, Ulrich Koszinowski and Thomas Brocker. MHC class I cross-presentation by dendritic cells counteracts viral immune evasion. Frontiers in Immunology. November 2012. Volume 3, Article 348. doi: 10.3389/fimmu.2012.00348
38. Argnani R, Marconi P, Volpi I, Bolanos E, Carro E, Ried C, Santamaria E, Pourchet A, Epstein A.L, Brocker T, Corrales F.J, Manservigi R, Goicoechea I, Foschini M, Hernandez-Alcoceba R. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver International 2011: 1542-1553
39. Mattoli F., Tiribuzi R., D’Angelo F., Di Girolamo I., Quattrocelli M., Montesano S., Crispoltoni L., Oikonomou V., Cusella De Angelis M. G., Marconi P., Orlacchio A., Sampaolesi M., Martino S. and Orlacchio A. Development of a New Tool for 3D Modeling for Regenerative Medicine. International Journal of Biomedical Imaging. 2011, Article ID 236854, 13 pages
40. Fraefel C, Marconi P, Epstein AL. Herpes Simplex Virus Type 1-Derived Recombinant and Amplicon Vectors. Methods Mol. Biol. 2011: 737:303-343
41. Edelman SL, Marconi P, Brocker T. Peripheral T cells re-enter the thymus and interfere with central tolerance induction. J Immunol. 2011 May 15; 186 (10): 5612-9. Epub 2011 Apr 6
42. Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P, Marzola A, Mora GN, Fabene PF, Simonato M: Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 2011.
43. Marconi P, Manservigi R, Epstein AL: HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel 2010, 13:169-183.
44. Manservigi R, Argnani R, Marconi P*: HSV Recombinant Vectors for Gene Therapy. Open Virol J 2010, 4:123-156. (*Corresponding Author)
45. Gruber A, Cannarile MA, Cheminay C, Ried C, Marconi P, Hacker G, Brocker T: Parenchymal cells critically curtail cytotoxic T-cell responses by inducing Bim-mediated apoptosis. Eur J Immunol 2010, 40:966-975.
46. Foka P, Pourchet A, Hernandez-Alcoceba R, Doumba PP, Pissas G, Kouvatsis V, Dalagiorgou G, Kazazi D, Marconi P, Foschini M, et al.: Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J Gene Med 2010, 12:956-967.
47. Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, Navarro Mora G, Osculati F, Berto E, Marconi P, Marzola A, et al.: Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 2010, 7:81.
48. Santamaria E, Mora MI, Carro-Roldan E, Molina M, Fernandez-Irigoyen J, Marconi P, Manservigi R, Greco A, Epstein AL, Prieto J, et al.: Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft. J Proteomics 2009, 73:153-160.
49. Paradiso B,° Marconi P,° Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Navarro Mora G, et al.: Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A 2009, 106:7191-7196. (°The authors contributed equally to this paper)
50. Marconi P*, Argnani R, Epstein AL, Manservigi R: HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol 2009, 655:118-144. (*Corresponding Author)
51. Marconi P., Argnani R., Epstein A. L., Manservigi R. (2009). HSV as a vector in vaccine development and gene therapy. Pharmaceutical Biotechnology. p. 118-144, Carlos A. Guzman & Giora Feuerstein. Landes Biosci, ISBN/ISSN: 978-1-4419-1131-5.
52. Marconi P*, Argnani R, Berto E, Epstein AL, Manservigi R: HSV as a vector in vaccine development and gene therapy. Hum Vaccine 2008, 4:91-105 (*Corresponding Author)
53. Luckashenak N, Schroeder S, Endt K, Schmidt D, Mahnke K, Bachmann MF, Marconi P, Deeg CA, Brocker T: Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008, 28:521-532.
54. Dresch C, Edelmann SL, Marconi P, Brocker T: Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008, 181:4495-4506.
55. Werner-Klein M, Dresch C, Marconi P, Brocker T: Transcriptional targeting of B cells for induction of peripheral CD8 T cell tolerance. J Immunol 2007, 178:7738-7746.
56. Furlan R, Bergami A, Brambilla E, Butti E, De Simoni MG, Campagnoli M, Marconi P, Comi G, Martino G: HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2007, 14:93-98.
57. Fiorentini S, ° Marconi P, ° Avolio M, Marini E, Garrafa E, Caracciolo S, Rossi D, Bozac A, Becker PD, Gentili F, et al.: Replication-deficient mutant Herpes Simplex Virus-1 targets professional antigen presenting cells and induces efficient CD4+ T helper responses. Microbes and Infection 2007, 9:988-996. (°The authors contributed equally to this paper)
58. Berto E, Bozac A, Volpi I, Lanzoni I, Vasquez F, Melara N, Manservigi R, Marconi P*: Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. Cancer Gene Ther 2007, 14:791-801. (*Corresponding Authors)
59. Manservigi R., Argnani R., Marconi P., Epstein A (2007). Herpesvirus-based vectors for gene transfer, gene therapy and the development of novel vaccines. Virus Expression Vectors 2007. p. 205-246, Kerala: Kathleen L. Hefferon
60. Fiorentini S, Becker PD, Marini E, Marconi P, Avolio M, Tosti G, Link C, Manservigi R, Guzman CA, Caruso A: HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens. Viral Immunol 2006, 19:177-188.
61. Bozac A, Berto E, Vasquez F, Grandi P, Caputo A, Manservigi R, Ensoli B, Marconi P*: Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine 2006, 24:7148-7158. (*Corresponding Authors)
62. Martino S, ° Marconi P,° Tancini B, Dolcetta D, De Angelis MG, Montanucci P, Bregola G, Sandhoff K, Bordignon C, Emiliani C, et al.: A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 2005, 14:2113-2123. (°The authors contributed equally to this paper)
63. Marconi P, Zucchini S, Berto E, Bozac A, Paradiso B, Bregola G, Grassi C, Volpi I, Argnani R, Marzola A, et al.: Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo. Gene Ther 2005, 12:559-569.
64. Lauterbach H, Ried C, Epstein AL, Marconi P, Brocker T: Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 2005, 86:2401-2410.
65. Epstein AL, Marconi P, Argnani R, Manservigi R: HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther 2005, 5:445-458.
66. Berto E, Bozac A, Marconi P*. Development and application of replication-incompetent HSV-1-based vectors. Gene Ther 2005, 12 Suppl 1:S98-102. (*Corresponding Authors)
67. Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P, Manservigi R, Gariglio M, Landolfo S: The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res 2004, 293:331-345.
68. Lauterbach H, Kerksiek KM, Busch DH, Berto E, Bozac A, Mavromara P, Manservigi R, Epstein AL, Marconi P,^ Brocker T^: Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 2004, 78:4020-4028. (^Corresponding Authors and Shared senior authorship)
69. Argnani R, Boccafogli L, Marconi PC, Manservigi R: Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Ther 2004, 11:1087-1098.
70. Furlan R, Pluchino S, Marconi PC, Martino G: Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. Methods Mol Biol 2003, 215:279-289.
71. Goins WF, Marconi P, Krisky D, Wolfe D, Glorioso JC, Ramakrishnan R, Fink DJ: Construction of replication-defective herpes simplex virus vectors. Curr Protoc Hum Genet 2002, Chapter 12:Unit 12 11.
72. Ruffini F, Furlan R, Poliani PL, Brambilla E, Marconi PC, Bergami A, Desina G, Glorioso JC, Comi G, Martino G: Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2001, 8:1207-1213.
73. Poliani PL, Brok H, Furlan R, Ruffini F, Bergami A, Desina G, Marconi PC, Rovaris M, Uccelli A, Glorioso JC, et al.: Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001, 12:905-920.
74. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L, Glorioso JC, Comi G, Martino G: Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther 2001, 8:13-19.
75. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, et al.: Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001, 167:1821-1829.
76. Furlan R, Poliani P.L., Bergami A., Ruffini F., Brambilla E., Marconi P., Comi G., Martino G.. Immunogene therapy for autoimmune demyelination In: Brain Diseases: Therapeutic Strategies and Repair. Immune-mediated brain injuries. Miller A., Abramsky O., Compston D., Said G. (Eds.). Martin Dunitz, London. 2001, pp 11.1-11.7.
77. Simonato M, Manservigi R, Marconi P, Glorioso J: Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. Trends Neurosci 2000, 23:183-190.
78. Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, Yoshimine T, Cohen JB, Glorioso JC: HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther 2000, 7:1483-1490.
79. Martino G, Poliani PL, Marconi PC, Comi G, Furlan R: Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors. Gene Ther 2000, 7:1087-1093.
80. Martino G, Poliani PL, Furlan R, Marconi P, Glorioso JC, Adorini L, Comi G: Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J Neuroimmunol 2000, 107:184-190.
81. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF, Cohen JB, Glorioso JC: Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther 2000, 1:71-81.
82. Gomez-Navarro J, Contreras JL, Arafat W, Jiang XL, Krisky D, Oligino T, Marconi P, Hubbard B, Glorioso JC, Curiel DT, et al.: Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 2000, 7:43-52.
83. Martino G., Furlan R., Poliani P.L., Bergami A., Desina G., Comi G., Marconi P. Gene Therapy: a possible future option for multiple sclerosis. In: Advances in Multiple Sclerosis. Clinical Research and Therapy. S.Fredrikson and H. Link eds.. Martin Dunitz, London, 1999: 125-136;
84. Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC: Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 1999, 159:34-46.
85. Simonato M, Marconi P, Glorioso J, Manservigi R: Molecular analysis of behavior by gene transfer into neurons with herpes simplex vectors. Brain Res 1999, 835:37-45.
86. Marconi P, Simonato M, Zucchini S, Bregola G, Argnani R, Krisky D, Glorioso JC, Manservigi R: Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther 1999, 6:904-912.
87. Laquerre S., Goins W.F., Moriuchi S., Oligino T., Krisky D.M., Marconi P., Soares M.K., Cohen J.B., Fink D.J., and Glorioso J.C. Gene transfer tool: Herpes simplex virus vectors. In The Development of Human Gene Therapy. Theodore Friedmann (ed.), Cold Spring Harbor Laboratory Press, NY, 1998.
88. Goins, W.F., Marconi P, Krisky, D., Ramakrishnan, R., Fink, D.J., and Glorioso, J.C. Construction of Replication Defective Herpes Simplex Virus Vectors. In Current Protocols in Human Genetics, E. Nabel (ed.), John Wiley Sons, Inc., 1997.
89. Goins W.F., Oligino T., Krisky D., Marconi P, Poliani P.L., Ramakrishnan R., Fink D.J., Glorioso J.C..Herpes Simplex Virus mediated gene transfer to neurons. in Concepts in Gene Therapy. Michael Strauss M. and Barranger J. A. (eds.). Berlin; New York: de Gruyter, 1997.
90. Oligino T., Krisky D., Marconi P., Fink D.J., and Glorioso, J.C. Herpes simplex gene therapy vectors for the treatment of cancer. Chapter in: Advances in Neuro-Oncology, M Walker and P. Korblith (eds.) Future Publishing Company, Inc. Ny. 1997.
91. Glorioso J.C., Krisky D., Marconi P., Oligino T., S. Ghivizzani, P.D. Robbins, M. Schmidt, W.F. Goins, and C. Evans: Progress in development of herpes simplex virus gene vectors for the treatment of rheumatoid arthritis, Chapter in Advanced Drug Delivery Reviews, B.L. Davidson (ed.) Elsevier, 1997.
92. Huard, J., Krisky D., Oligino T., Marconi P., Day C.S., Watkins, S.C., Glorioso, J.C. Gene transfer to muscle using herpes simplex virus-based vectors. Chapter in Concepts in gene therapy. M.Strauss and J. Barranger (eds.) Walter De Gruyrter and Co. Berlin, 1997.
93. Huard J., Goins W.F., Akkaraju G.R., Krisky D., Oligino T., Marconi P, and Glorioso J.C. Gene transfer to muscle and spinal cord using herpes simplex virus-based vectors. In Gene Therapy Technologies and Regulations from Laboratory to Clinic, A. Meager (ed.), John Wiley & Sons, Inc., 1997.
94. Krisky, D., Marconi P, Goins, W.F., and Glorioso, J.C. Development of Replication-Defective Herpes Simplex Virus Vectors. Chapter in Methods in Molecular Medicine, Gene Therapy Protocols, P.Robbins (ed.) Humana Press Inc. Totowa, N.J. 1996.
95. Wang M, Rancourt C, Navarro JG, Krisky D, Marconi P, Oligino T, Alvarez RD, Siegal GP, Glorioso JC, Curiel DT: High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol Oncol 1998, 71:278-287.
96. van Deutekom JC, Floyd SS, Booth DK, Oligino T, Krisky D, Marconi P, Glorioso JC, Huard J: Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscul Disord 1998, 8:135-148.
97. Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J, Glorioso JC: Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 1998, 58:5731-5737.
98. Kuklin NA, Daheshia M, Marconi PC, Krisky DM, Rouse RJ, Glorioso JC, Manican E, Rouse BT: Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology 1998, 240:245-253.
99. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 1998, 5:1593-1603.
100. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB, Watkins SC, Glorioso JC: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 1998, 5:1517-1530.
101. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso JC: Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 1997, 4:1120-1125.
102. Huard J, Krisky D, Oligino T, Marconi P, Day CS, Watkins SC, Glorioso JC: Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord 1997, 7:299-313.
103. Goins WF, Krisky D, Marconi P, Oligino T, Ramakrishnan R, Poliani PL, Fink DJ, Glorioso JC: Herpes simplex virus vectors for gene transfer to the nervous system. J Neurovirol 1997, 3 Suppl 1:S80-88.
104. Glorioso JC, Goins WF, Schmidt MC, Oligino T, Krisky DM, Marconi PC, Cavalcoli JD, Ramakrishnan R, Poliani PL, Fink DJ: Engineering herpes simplex virus vectors for human gene therapy. Adv Pharmacol 1997, 40:103-136.
105. Evans C, Goins WF, Schmidt MC, Robbins PD, Ghivizzani SC, Oligino T, Marconi P, Krisky D, Glorioso JC: Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis. Adv Drug Deliv Rev 1997, 27:41-57.
106. Oligino T, Poliani PL, Marconi P, Bender MA, Schmidt MC, Fink DJ, Glorioso JC: In vivo transgene activation from an HSV-based gene therapy vector by GAL4:VP16. Gene Ther 1996, 3:892-899.
107. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF, Fink DJ, Glorioso JC: Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A 1996, 93:11319-11320.
108. Caputo A, Grossi MP, Bozzini R, Rossi C, Betti M, Marconi PC, Barbanti-Brodano G, Balboni PG: Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Ther 1996, 3:235-245.
109. Fink DJ, Ramakrishnan R, Marconi P, Goins WF, Holland TC, Glorioso JC: Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Clin Neurosci 1995, 3:284-291.
110. Grossi MP, Caputo A, Zucchini S, Bozzini R, Marconi PC, Manservigi R, Barbanti-Brodano G, Balboni PG: Molecular approaches to inhibit HIV-1 tat expression and functions. Year Immunol 1993, 7:199-204.
111. Balboni PG, Bozzini R, Zucchini S, Marconi PC, Grossi MP, Caputo A, Manservigi R, Barbanti-Brodano G: Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant. J Med Virol 1993, 41:289-295.
112. Grossi M.P., Caputo A., Zucchini S., Bozzini R., Marconi P.C., Manservigi R., Barbanti-Brodano G., and Balboni P.G. Molecular approaches to inhibit HIV-1 tat expression and functions. In "Generation of Antibodies by Cell and Gene Immortalization" C. Terhorst, F. Malavasi & A. Albertini (eds.), Basel, S. Karger, Year Immunol. vol.7, pp.199-204, 1993.
113. Sabbioni S., Negrini M., Marconi P.C. and Manservigi R. Detection of Herpes simplex virus type-specific antibody with recombinant glycoprotein G. In "European Biotechnology Today. The impact of basic sciences on diagnosis and therapy" F. Malavasi, R. Cortese, and A. Albertini (Eds.). Andover (UK), Intercept Ltd., pp. 235-243, 1992
